EGFR and non-small cell lung carcinoma: Interestingly, in a cohort of 383 chemo- and/or radio-naïve non-small cell lung cancer (NSCLC) patients we found that p65BTK was expressed in more than half of them and its levels were significantly higher in never-smokers and in EGFR-wt tumors, therefore suggesting that p65BTK could be a novel target in advanced NSCLC EGFR-wt non-smokers patients that are not eligible for targeted therapy (Giordano et al., 2019).